Vadastuximab disitamab vedotin antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a marker https://arunxxzs576737.blogdigy.com/vadastuximab-a-deep-dive-into-cd33-targeted-therapy-65344609